NCT06035224View on ClinicalTrials.gov

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
Interventions
DRUG

AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally

AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.

Trial Locations (1)

200123

RECRUITING

Shanghai Renji Hospital, Shanghai

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

lead

RenJi Hospital

OTHER